Brief: Bristol Myers Squibb Presents First Clinical Data From Two Phase 3 Studies In The Adept Program Evaluating Karxt For Psychosis Associated With Alzheimer’S Disease
BRIEF-Bristol Myers Squibb Presents First Clinical Data From Two Phase 3 Studies In The Adept Program Evaluating Karxt For Psychosis Associated With Alzheimer’S Disease Nov 18 (Reuters) - Bristol-Myers Squibb Company BMY.N:
BRISTOL MYERS SQUIBB PRESENTS FIRST CLINICAL DATA FROM TWO PHASE 3 STUDIES IN THE ADEPT PROGRAM EVALUATING KARXT FOR PSYCHOSIS ASSOCIATED WITH ALZHEIMER’S DISEASE
BRISTOL-MYERS SQUIBB COMPANY - ADEPT-1 SHOWS MEAN REDUCTION OF 1.9 POINTS ON CGI-S SCORE
BRISTOL-MYERS SQUIBB COMPANY - ADEPT-1 SHOWS MEAN REDUCTION OF 12.0 POINTS ON NPI-C H+D SCALE
BRISTOL-MYERS SQUIBB COMPANY: KARXT WAS GENERALLY WELL TOLERATED ACROSS BOTH STUDIES WITH NO NEW SAFETY SIGNALS IDENTIFIED
BRISTOL-MYERS SQUIBB COMPANY - ADEPT-3 SHOWS MEAN REDUCTION OF 5.1 POINTS ON NPI-C H+D SCALE, 0.8 ON CGI-S
Source text: ID:nBw583ZWwa
Further company coverage: BMY.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bristol-Myers Squibb
See all newsEvotec rises after second FDA IND acceptance in Bristol Myers Squibb partnership
AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco
Bristol's schizophrenia drug helps Alzheimer's-related psychosis symptoms, preliminary data shows
Brief: Bristol Myers Squibb Presents First Clinical Data From Two Phase 3 Studies In The Adept Program Evaluating Karxt For Psychosis Associated With Alzheimer’S Disease
Brief: Sichuan Biokin Pharmaceutical's Unit Receives Milestone Payment From Bristol-Myers Squibb